

# GETINGE Interim Report

January – March 2009

April 21, 2009

Johan Malmquist, CEO

Ulf Grunander, CFO



## Q1 2009 Highlights

- Challenging demand situation for medical capital equipment in the US
- Datascope acquisition completed
- Integration of Datascope initiated

## Q1 2009 DEVELOPMENT OF ORGANIC ORDER INTAKE

	2009 Q1			
	MS	EC	IC	TOT
Europe	2,7%	-12.2%	0,8%	-4.2%
USA and Canada	-10.1%	-7.2%	-10.5%	-9.3%
Asia and Australia	16.5%	-8.6%	5.0%	6.9%
Rest of the world	-21.2%	65.2%	-66.2%	-22.6
<b>Total</b>	<b>-2.3%</b>	<b>-9.5%</b>	<b>-5.2%</b>	<b>-5.5%</b>

- *Adj for currency fluctuations and corporate acquisitions*

- Currency gain of 228 MSEK

	2009 Q1	2008 Q1	Change %
Net sales	<b>5 153</b>	4 107	25,5%
Gross margin	<b>49,1%</b>	50,3%	-1,2%
Operating cost	<b>-2 010</b>	-1 500	34.1%
EBITA before restructuring	<b>652</b>	649	0,5%
%	<b>12,7%</b>	15,8%	-3,1%
Restructuring	<b>37</b>	23	
Financial net	<b>46</b>	-182	
Profit before tax	<b>530</b>	363	46%

- *SEK Million*

## MEDICAL SYSTEMS


### Q1 2009 RESULTS

	2009 Q1	2008 Q1	Change %
Net sales	<b>2 453</b>	1 786	37.3%
Gross margin %	<b>56.5%</b>	57.3%	-0.8%
Operating cost	<b>- 1 137</b>	-740	53.6%
EBITA before restructuring	<b>346</b>	331	4.5%
%	<b>14.1%</b>	18.5%	-4.4%
Restructuring	<b>-11</b>	-3	

▪ *SEK Million*

## MEDICAL SYSTEMS Q1 2009 HIGHLIGHTS

- Integration of the Boston Scientific Cardiac and Vascular Surgery divisions on track
- Datascope integration initiated
- FLOW-i to be launched in June at ESA
- Successful FUSION GRAFT patient implantations




## EXTENDED CARE Q1 2009 RESULTS

	2009 Q1	2008 Q1	Change %
Net sales	<b>1 649</b>	1 398	18%
Gross margin %	<b>45.8%</b>	49.6%	-3.8%
Operating cost	<b>-553</b>	-486	13.8%
EBITA before restructuring	<b>231</b>	235	-1.7%
%	<b>14.0%</b>	16.8%	-2.8%
Restructuring	<b>-26</b>	-19	

- *SEK Million*

## EXTENDED CARE Q1 2009 HIGHLIGHTS

- Merger of Extended Care and Huntleigh sales companies in USA will result in annual cost savings of USD 7 million
- Program initiated to reduce cost of logistics and transportation





## INFECTION CONTROL Q1 2009 RESULTS

	2009 Q1	2008 Q1	Change %
Net sales	<b>1 051</b>	924	13,7%
Gross margin %	<b>37.2%</b>	38.1%	-0.9%
Operating cost	<b>-321</b>	-273	17.6%
EBITA before restructuring	<b>74</b>	83	-10.8
%	<b>7.0%</b>	9.0%	-2.0%
Restructuring		-1	

- *SEK Million*

## INFECTION CONTROL Q1 2009 HIGHLIGHTS

- Strong interest and orders for recently launched ED-flow endoscope re-processor
- New sales company in India
- Acquisition of Numac Validation Serviced Ltd.



# THE GETINGE GROUP FINANCIALS

	2009 Q1	2008 Q1	2008 FY
Operating cash flow	1 040	928	3 067
Net Debt	19 366	12 829	13 468
Equity	11 345	7 820	10 676
Equity/assets ratio, per cent	28.1	28.2	32.3
Net debt/equity ratio multiple	1.71	1.64	1.26

- *SEK Million*

## Revised Outlook

- We expect organic revenue growth of 2-3 % in 2009
- We expect pre tax profit including integration cost related do Datascope acquisition to grow by approximately 15 %.

# QUESTIONS & ANSWERS

GETINGE



## THE GETINGE GROUP

### FORWARD LOOKING INFORMATION

This document contains forward-looking information based on the current expectations of the Getinge Group's management. Although management deems that the expectations presented by such forward-looking information are reasonable, no guarantee can be given that these expectations will prove correct. Accordingly, the actual future outcome could vary considerably compared with what is stated in the forward-looking information, due to such factors as changed conditions regarding business cycles, market and competition, changes in legal requirements and other political measures, and fluctuations in exchange rates.